<rdf:RDF xmlns:api="http://www.elsevier.com/xml/svapi/rdf/dtd/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/77954632414"><dc:identifier>https://api.elsevier.com/content/abstract/eid/2-s2.0-77954632414</dc:identifier><api:scopusId>77954632414</api:scopusId><api:eid>2-s2.0-77954632414</api:eid><api:pubmedId>20647198</api:pubmedId><api:pui>359181046</api:pui><api:pii>S002847931465440X</api:pii><prism:doi>10.1056/NEJMoa0909169</prism:doi><dc:title>Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis</dc:title><prism:issn>15334406</prism:issn><prism:issn>00284793</prism:issn><prism:contentType>Abstract</prism:contentType><prism:aggregationType>Journal</prism:aggregationType><api:srctype>j</api:srctype><api:subtype>ar</api:subtype><api:subtypeDescription>Article</api:subtypeDescription><api:citedbyCount>764</api:citedbyCount><prism:publicationName>New England Journal of Medicine</prism:publicationName><dc:publisher> Massachussetts Medical Society </dc:publisher><api:sourceId>15847</api:sourceId><prism:volume>363</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:startingPage>211</prism:startingPage><prism:endingPage>220</prism:endingPage><prism:pageRange>211-220</prism:pageRange><prism:coverDate>2010-07-15</prism:coverDate><prism:copyrightYear>2010</prism:copyrightYear><dc:creator><rdf:Seq><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/45761212800"><api:authid>45761212800</api:authid><api:surname>Jones</api:surname><api:givenName>Rachel B.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60017488"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7003559165"><api:authid>7003559165</api:authid><api:surname>Tervaert</api:surname><api:givenName>Jan Willem Cohen</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60007895"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/36795395200"><api:authid>36795395200</api:authid><api:surname>Hauser</api:surname><api:givenName>Thomas</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60019619"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7003619596"><api:authid>7003619596</api:authid><api:surname>Luqmani</api:surname><api:givenName>Raashid</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60009946"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/8266079100"><api:authid>8266079100</api:authid><api:surname>Morgan</api:surname><api:givenName>Matthew D.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/107138059"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/6602457446"><api:authid>6602457446</api:authid><api:surname>Peh</api:surname><api:givenName>Chen Au</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60031564"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7201826182"><api:authid>7201826182</api:authid><api:surname>Savage</api:surname><api:givenName>Caroline O.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/107138059"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/6701867637"><api:authid>6701867637</api:authid><api:surname>Segelmark</api:surname><api:givenName>Mårten</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60014077"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7102290100"><api:authid>7102290100</api:authid><api:surname>Tesar</api:surname><api:givenName>Vladimir</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60016605"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/8671083100"><api:authid>8671083100</api:authid><api:surname>Van Paassen</api:surname><api:givenName>Pieter</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60007895"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7402053536"><api:authid>7402053536</api:authid><api:surname>Walsh</api:surname><api:givenName>Dorothy</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60017488"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7402337886"><api:authid>7402337886</api:authid><api:surname>Walsh</api:surname><api:givenName>Michael</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60017488"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/17737049100"><api:authid>17737049100</api:authid><api:surname>Westman</api:surname><api:givenName>Kerstin</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60010392"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7006525072"><api:authid>7006525072</api:authid><api:surname>Jayne</api:surname><api:givenName>David R.W.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60017488"/></api:Author></rdf:li></rdf:Seq></dc:creator><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2700"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/61449238213"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/66149168812"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0038122889"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/34447285291"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/46849114754"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0345337254"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/2942537697"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33746961890"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33646483031"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/38149063749"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/27844456394"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0033065098"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/25444502877"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33745697938"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33646381359"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0020051506"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/75149134390"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33749331884"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/34548492958"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/67650094918"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/31944440872"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/12344330217"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33750214245"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/77954651554"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0028158243"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0025183423"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33746848347"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/72249087511"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0033574249"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/3142560498"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0031042957"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0035841813"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/39749124664"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0025786860"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/34249297664"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0037380194"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0018778115"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33745609792"/><api:article rdf:resource="https://api.elsevier.com/content/article/eid/1-s2.0-S002847931465440X"/><api:scopusPage rdf:resource="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=77954632414&amp;origin=inward"/></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60017488"><api:afid>60017488</api:afid><skos:prefLabel>Addenbrooke's Hospital</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60009946"><api:afid>60009946</api:afid><skos:prefLabel>Nuffield Orthopaedic Centre NHS Trust</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/107138059"><api:afid>107138059</api:afid><skos:prefLabel>College of Medical and Dental Sciences</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60007895"><api:afid>60007895</api:afid><skos:prefLabel>University Hospital Maastricht</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60019619"><api:afid>60019619</api:afid><skos:prefLabel>UniversitatsSpital Zurich</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60031564"><api:afid>60031564</api:afid><skos:prefLabel>Royal Adelaide Hospital</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60014077"><api:afid>60014077</api:afid><skos:prefLabel>Skånes universitetssjukhus</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60010392"><api:afid>60010392</api:afid><skos:prefLabel>Malmo University Hospital</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60016605"><api:afid>60016605</api:afid><skos:prefLabel>Charles University</skos:prefLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2700"><api:code>2700</api:code><api:abbrev>MEDI</api:abbrev><skos:prefLabel>Medicine (all)</skos:prefLabel><skos:altLabel>Medicine</skos:altLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/61449238213"><api:scopusId>61449238213</api:scopusId><dc:title>EULAR recommendations for the management of primary small and medium vessel vasculitis</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>68</prism:volume><prism:startingPage>310</prism:startingPage><prism:endingPage>317</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/66149168812"><api:scopusId>66149168812</api:scopusId><dc:title>Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial</dc:title><prism:publicationName>Ann Intern Med</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>150</prism:volume><prism:startingPage>670</prism:startingPage><prism:endingPage>680</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0038122889"><api:scopusId>0038122889</api:scopusId><dc:title>A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies</dc:title><prism:publicationName>New England Journal of Medicine</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>349</prism:volume><prism:startingPage>36</prism:startingPage><prism:endingPage>44</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/34447285291"><api:scopusId>34447285291</api:scopusId><dc:title>Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis</dc:title><prism:publicationName>J Am Soc Nephrol</prism:publicationName><prism:publicationYear>2007</prism:publicationYear><prism:volume>18</prism:volume><prism:startingPage>2180</prism:startingPage><prism:endingPage>2188</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/46849114754"><api:scopusId>46849114754</api:scopusId><dc:title>Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>67</prism:volume><prism:startingPage>1004</prism:startingPage><prism:endingPage>1010</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0345337254"><api:scopusId>0345337254</api:scopusId><dc:title>Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program</dc:title><prism:publicationName>J Clin Oncol</prism:publicationName><prism:publicationYear>1998</prism:publicationYear><prism:volume>16</prism:volume><prism:startingPage>2825</prism:startingPage><prism:endingPage>2833</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/2942537697"><api:scopusId>2942537697</api:scopusId><dc:title>Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis</dc:title><prism:publicationName>New England Journal of Medicine</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>350</prism:volume><prism:startingPage>2572</prism:startingPage><prism:endingPage>2581</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33746961890"><api:scopusId>33746961890</api:scopusId><dc:title>Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>54</prism:volume><prism:startingPage>2793</prism:startingPage><prism:endingPage>2806</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33646483031"><api:scopusId>33646483031</api:scopusId><dc:title>The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>54</prism:volume><prism:startingPage>1390</prism:startingPage><prism:endingPage>1400</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/38149063749"><api:scopusId>38149063749</api:scopusId><dc:title>Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>35</prism:volume><prism:startingPage>20</prism:startingPage><prism:endingPage>30</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/27844456394"><api:scopusId>27844456394</api:scopusId><dc:title>BAFF is elevated in serum of patients with Wegener's granulomatosis</dc:title><prism:publicationName>Journal of Autoimmunity</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>25</prism:volume><prism:startingPage>298</prism:startingPage><prism:endingPage>302</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0033065098"><api:scopusId>0033065098</api:scopusId><dc:title>Differential B- and T-cell activation in Wegener's granulomatosis</dc:title><prism:publicationName>J Allergy Clin Immunol</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>103</prism:volume><prism:startingPage>885</prism:startingPage><prism:endingPage>894</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/25444502877"><api:scopusId>25444502877</api:scopusId><dc:title>Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production</dc:title><prism:publicationName>Annals of the New York Academy of Sciences</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>1051</prism:volume><prism:startingPage>12</prism:startingPage><prism:endingPage>19</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33745697938"><api:scopusId>33745697938</api:scopusId><dc:title>B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>65</prism:volume><prism:startingPage>859</prism:startingPage><prism:endingPage>864</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33646381359"><api:scopusId>33646381359</api:scopusId><dc:title>Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies</dc:title><prism:publicationName>Journal of the American Society of Nephrology</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>17</prism:volume><prism:startingPage>1235</prism:startingPage><prism:endingPage>1242</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0020051506"><api:scopusId>0020051506</api:scopusId><dc:title>Suppression of human B lymphocyte function by cyclophosphamide</dc:title><prism:publicationName>J Immunol</prism:publicationName><prism:publicationYear>1982</prism:publicationYear><prism:volume>128</prism:volume><prism:startingPage>2453</prism:startingPage><prism:endingPage>2457</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/75149134390"><api:scopusId>75149134390</api:scopusId><dc:title>Role of rituximab therapy in glomerulonephritis</dc:title><prism:publicationName>J Am Soc Nephrol</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>21</prism:volume><prism:startingPage>14</prism:startingPage><prism:endingPage>17</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33749331884"><api:scopusId>33749331884</api:scopusId><dc:title>Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>54</prism:volume><prism:startingPage>2970</prism:startingPage><prism:endingPage>2982</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/34548492958"><api:scopusId>34548492958</api:scopusId><dc:title>Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: Past, present and future</dc:title><prism:publicationName>Kidney International</prism:publicationName><prism:publicationYear>2007</prism:publicationYear><prism:volume>72</prism:volume><prism:startingPage>676</prism:startingPage><prism:endingPage>682</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/67650094918"><api:scopusId>67650094918</api:scopusId><dc:title>A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>60</prism:volume><prism:startingPage>2156</prism:startingPage><prism:endingPage>2168</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/31944440872"><api:scopusId>31944440872</api:scopusId><dc:title>Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial</dc:title><prism:publicationName>American Journal of Respiratory and Critical Care Medicine</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>173</prism:volume><prism:startingPage>180</prism:startingPage><prism:endingPage>187</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/12344330217"><api:scopusId>12344330217</api:scopusId><dc:title>Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>52</prism:volume><prism:startingPage>262</prism:startingPage><prism:endingPage>268</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33750214245"><api:scopusId>33750214245</api:scopusId><dc:title>Long-term observations of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab</dc:title><prism:publicationName>Rheumatology</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>45</prism:volume><prism:startingPage>1432</prism:startingPage><prism:endingPage>1436</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/77954651554"><api:scopusId>77954651554</api:scopusId><dc:title>Rituximab versus cyclophosphamide for ANCA-associated vasculitis</dc:title><prism:publicationName>N Engl J Med</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>363</prism:volume><prism:startingPage>221</prism:startingPage><prism:endingPage>232</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0028158243"><api:scopusId>0028158243</api:scopusId><dc:title>Nomenclature of systemic vasculitides: Proposal of an international consensus conference</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>1994</prism:publicationYear><prism:volume>37</prism:volume><prism:startingPage>187</prism:startingPage><prism:endingPage>192</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0025183423"><api:scopusId>0025183423</api:scopusId><dc:title>The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>1990</prism:publicationYear><prism:volume>33</prism:volume><prism:startingPage>1101</prism:startingPage><prism:endingPage>1107</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33746848347"><api:scopusId>33746848347</api:scopusId><dc:title>Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use</dc:title><prism:publicationName>Med Etika Bioet</prism:publicationName><prism:publicationYear>2002</prism:publicationYear><prism:volume>9</prism:volume><prism:startingPage>12</prism:startingPage><prism:endingPage>19</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/72249087511"><api:scopusId>72249087511</api:scopusId><dc:title>Modification and validation of the Birmingham Vasculitis Activity Score (version 3)</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>68</prism:volume><prism:startingPage>1827</prism:startingPage><prism:endingPage>1832</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0033574249"><api:scopusId>0033574249</api:scopusId><dc:title>A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation</dc:title><prism:publicationName>Annals of Internal Medicine</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>130</prism:volume><prism:startingPage>461</prism:startingPage><prism:endingPage>470</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/3142560498"><api:scopusId>3142560498</api:scopusId><dc:title>The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts: Results from the Medical Outcomes Study</dc:title><prism:publicationName>Med Care</prism:publicationName><prism:publicationYear>1992</prism:publicationYear><prism:volume>30</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0031042957"><api:scopusId>0031042957</api:scopusId><dc:title>Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>1997</prism:publicationYear><prism:volume>40</prism:volume><prism:startingPage>371</prism:startingPage><prism:endingPage>380</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0035841813"><api:scopusId>0035841813</api:scopusId><dc:title>Statistics notes: Analysing controlled trials with baseline and follow up measurements</dc:title><prism:publicationName>BMJ</prism:publicationName><prism:publicationYear>2001</prism:publicationYear><prism:volume>323</prism:volume><prism:startingPage>1123</prism:startingPage><prism:endingPage>1124</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/39749124664"><api:scopusId>39749124664</api:scopusId><dc:title>BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis</dc:title><prism:publicationName>Rheumatology</prism:publicationName><prism:publicationYear>2007</prism:publicationYear><prism:volume>46</prism:volume><prism:startingPage>1615</prism:startingPage><prism:endingPage>1616</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0025786860"><api:scopusId>0025786860</api:scopusId><dc:title>Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone only</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>1991</prism:publicationYear><prism:volume>34</prism:volume><prism:startingPage>945</prism:startingPage><prism:endingPage>950</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/34249297664"><api:scopusId>34249297664</api:scopusId><dc:title>Infectious complications of monoclonal antibodies used in cancer therapy: A systematic rewiew of the evidence from randomized controlled trials</dc:title><prism:publicationName>Cancer</prism:publicationName><prism:publicationYear>2007</prism:publicationYear><prism:volume>109</prism:volume><prism:startingPage>2182</prism:startingPage><prism:endingPage>2189</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0037380194"><api:scopusId>0037380194</api:scopusId><dc:title>Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study</dc:title><prism:publicationName>American Journal of Kidney Diseases</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>41</prism:volume><prism:startingPage>776</prism:startingPage><prism:endingPage>784</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0018778115"><api:scopusId>0018778115</api:scopusId><dc:title>Cyclophosphamide therapy of severe systemic necrotizing vasculitis</dc:title><prism:publicationName>N Engl J Med</prism:publicationName><prism:publicationYear>1979</prism:publicationYear><prism:volume>301</prism:volume><prism:startingPage>235</prism:startingPage><prism:endingPage>238</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33745609792"><api:scopusId>33745609792</api:scopusId><dc:title>Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment</dc:title><prism:publicationName>Rheumatology</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>45</prism:volume><prism:startingPage>724</prism:startingPage><prism:endingPage>729</prism:endingPage></rdf:Description></rdf:RDF>